{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-036977","form_type":"8-K","ticker":"BIXT","cik":"0001445815","company_name":"BIOXYTRAN, INC","filed_at":"2026-08-11T11:00:24+00:00","discovered_at":"2026-08-11T11:05:00.328631+00:00","generated_at":"2026-08-11T11:05:43.292421+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Bioxytran reports first CIDP patient on PLICID shows functional gains; no adverse events","bullets":["First CIDP patient treated with once-weekly IV PLICID regained finger use and ability to walk miles.","No adverse events reported during treatment; company cites case as supporting further evaluation.","PLICID is an ASI-designed galectin antagonist; Bioxytran plans a larger clinical study.","Company acknowledges single-patient observations are not sufficient to establish safety or efficacy."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-036977","json":"https://secwatch.observer/filing/0001493152-26-036977.json","markdown":"https://secwatch.observer/filing/0001493152-26-036977.md","text":"https://secwatch.observer/filing/0001493152-26-036977.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1445815/000149315226036977/0001493152-26-036977-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1445815/000149315226036977/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T11:05:43.292421+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}